Analyst Price Targets — SPRY
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| April 9, 2026 10:56 am | — | Northland Securities | $25.00 | $8.27 | TheFly | Northland starts disruptor ARS Pharmaceuticals with an Outperform |
| March 10, 2026 10:22 am | Roanna Ruiz | Leerink Partners | $26.00 | $9.28 | StreetInsider | ARS Pharmaceuticals Inc (SPRY) PT Raised to $26 at Leerink Partners |
| November 4, 2025 12:53 pm | Kyle Bauser | Roth Capital | $30.00 | $8.42 | TheFly | ARS Pharmaceuticals resumed with a Buy at Roth Capital |
| September 26, 2025 2:02 pm | — | Raymond James | $32.00 | $9.69 | TheFly | Raymond James positive on ARS Pharmaceuticals after weekly data |
| August 19, 2024 5:06 pm | Josh Schimmer | Cantor Fitzgerald | $30.00 | $14.24 | TheFly | ARS Pharmaceuticals initiated with an Overweight at Cantor Fitzgerald |
| August 12, 2024 4:28 pm | Strong Buy | Raymond James | $22.00 | $10.85 | TheFly | ARS Pharmaceuticals upgraded to Strong Buy from Outperform at Raymond James |
| July 25, 2024 6:30 am | Ryan Deschner | Raymond James | $18.00 | $10.40 | TheFly | ARS Pharmaceuticals initiated with an Outperform at Raymond James |
| March 5, 2024 6:07 am | Roanna Ruiz | Leerink Partners | $18.00 | $8.65 | StreetInsider | Leerink Partners Upgrades ARS Pharmaceuticals Inc (SPRY) to Outperform |
| December 13, 2022 6:10 am | — | Leerink Partners | $14.00 | $7.12 | Benzinga | SVB Leerink Initiates Coverage On ARS Pharmaceuticals with Outperform Rating, Announces Price Target of $14 |
Latest News for SPRY
NEW YORK, July 16, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of ARS Pharmaceuticals, Inc. ("ARS" or the "Company") (NASDAQ: SPRY). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
NEW YORK, July 14, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of ARS Pharmaceuticals, Inc. (“ARS” or the “Company”) (NASDAQ: SPRY). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
NEW YORK, July 9, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of ARS Pharmaceuticals, Inc. ("ARS" or the "Company") (NASDAQ: SPRY). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
On Tuesday, ARS Pharmaceuticals Inc. (NASDAQ:SPRY) announced a leadership transition. Co-founder and CEO Richard Lowenthal stepped down as an employee and officer, effective July 6, 2026.
NEW YORK, July 07, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of ARS Pharmaceuticals, Inc. (“ARS” or the “Company”) (NASDAQ: SPRY). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for SPRY.
U.S. House Trading
No House trades found for SPRY.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.